Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysis.

Aims: Systemic corticosteroids (SCS) are used to manage asthma exacerbations. Among the broad population of patients with asthma, SCS-related risk of adverse events (AEs), health care resource utilization (HCRU), and costs remain unclear.

Materials And Methods: This retrospective cohort study used the Optum Research Database claims to identify adults with asthma from 1/1/2017-6/30/2022.

Evaluation of a disease-state education program in asthma: Application of the Knowledge-to-Action Framework.

In patients with asthma, bronchoconstriction and airway inflammation both contribute to airway narrowing and airflow limitations, which lead to symptoms and exacerbations. Short-acting β₂-agonist (SABA)-only rescue therapy addresses only bronchoconstriction and is associated with increased morbidity and mortality. Current asthma management guidelines recommend concomitant treatment of symptoms and inflammation with a fast-acting bronchodilator and inhaled corticosteroid (ICS) as rescue therapy for patients ≥12 years of age.